Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axogen, Inc.AXGN · Entity 4297 | Chief Strategy and BD Officer | December 27, 2022 | December 30, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axogen, Inc.
Report date December 27, 2022 · Filed December 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,065 |
Ending reported balance
After 2022-12-27 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-12-27 · Exercise / conversion · Acquired 1,150 · Balance 25,392 F1: This reflects the number of restricted stock units that vested on December 27, 2022. Row 2 · 2022-12-27 · Tax withholding · Disposed 327 · Balance 25,065 F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-12-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-12-27 · Exercise / conversion · Acquired 1,150 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4: All shares of AxoGen Inc. common stock underlying the restricted stock units vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This reflects the number of restricted stock units that vested on December 27, 2022.
F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F4: All shares of AxoGen Inc. common stock underlying the restricted stock units vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 27, 2022 Filed Dec 30, 2022 01:52 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000143 · wf-form4_167236516296108.xml · derivative · entry 3 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock units vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. F4 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock units vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Read SEC document |
| December 27, 2022 Filed Dec 30, 2022 01:52 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 327 | $9.44 | $3,086.88 |
DisclosureSEC source: 0000805928-22-000143 · wf-form4_167236516296108.xml · nonDerivative · entry 2 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,065 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 27, 2022 Filed Dec 30, 2022 01:52 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000143 · wf-form4_167236516296108.xml · nonDerivative · entry 1 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This reflects the number of restricted stock units that vested on December 27, 2022. Read SEC document |
| July 19, 2022 Filed Jul 20, 2022 19:58 UTC | Axogen, Inc. AXGN · Entity 4297 | Disposition to issuerCommon Stock | 751 | $8.40 | $6,308.40 |
DisclosureSEC source: 0000805928-22-000090 · wf-form4_165834712363395.xml · nonDerivative · entry 2 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,242 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2022. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 19:58 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 2,571 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000090 · wf-form4_165834712363395.xml · nonDerivative · entry 1 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,340 F1 · shares: This reflects the number of shares that vested as of July 18, 2022 upon the attainment of certain performance criteria. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:01 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 23,354 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000027 · wf-form4_164763369289095.xml · derivative · entry 5 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,354 Underlying: Common Stock · 23,354 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F6 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F6 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:01 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 21,784 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0000805928-22-000027 · wf-form4_164763369289095.xml · derivative · entry 4 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,784 Underlying: Common Stock · 21,784 shares Expires 2032-03-16 F5 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2024 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:01 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000027 · wf-form4_164763369289095.xml · derivative · entry 3 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:01 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 2,447 | $7.97 | $19,502.59 |
DisclosureSEC source: 0000805928-22-000027 · wf-form4_164763369289095.xml · nonDerivative · entry 2 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,769 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:01 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000027 · wf-form4_164763369289095.xml · nonDerivative · entry 1 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,216 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:03 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 447 | $8.42 | $3,763.74 |
DisclosureSEC source: 0000805928-22-000007 · wf-form4_164513181764016.xml · nonDerivative · entry 2 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,716 F3 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 15, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:03 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 1,325 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000007 · wf-form4_164513181764016.xml · nonDerivative · entry 1 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,163 F1 · shares: This reflects the number of shares that became vested as of February 15, 2022 upon the attainment of certain performance criteria. F2 · balance_after: Includes 654 shares acquired under the Axogen stock purchase plan on December 31, 2021. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:15 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 1,150 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000178 · wf-form4_164081251560102.xml · derivative · entry 3 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,150 Underlying: Common Stock · 2,300 shares Expires 2022-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of theaggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting personupon the vesting date. F4 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of theaggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting personupon the vesting date. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:15 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 326 | $9.74 | $3,175.24 |
DisclosureSEC source: 0000805928-21-000178 · wf-form4_164081251560102.xml · nonDerivative · entry 2 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,184 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:15 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000178 · wf-form4_164081251560102.xml · nonDerivative · entry 1 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on December 27, 2021. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 20:13 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 728 | $19.20 | $13,977.60 |
DisclosureSEC source: 0000805928-21-000142 · wf-form4_162689841095311.xml · nonDerivative · entry 2 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,360 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2021. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 20:13 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 2,572 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000142 · wf-form4_162689841095311.xml · nonDerivative · entry 1 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,088 F1 · shares: This reflects the number of shares that became vested as of July 19, 2021 upon the attainment of certain performance criteria. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 21:56 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 11,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000065 · wf-form4_161610454800187.xml · derivative · entry 2 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,800 Underlying: Common Stock · 11,800 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 21:56 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 23,500 | $0.00 Strike: $20.91 | $0.00 |
DisclosureSEC source: 0000805928-21-000065 · wf-form4_161610454800187.xml · derivative · entry 1 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2031-03-16 F1 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2025 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 22:14 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 454 | $18.71 | $8,494.34 |
DisclosureSEC source: 0000805928-21-000020 · wf-form4_161368645399853.xml · nonDerivative · entry 2 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,080 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 16, 2021. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:14 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 1,325 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000020 · wf-form4_161368645399853.xml · nonDerivative · entry 1 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,534 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 16:51 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 649 | $17.81 | $11,558.69 |
DisclosureSEC source: 0001179110-20-012283 · edgar.xml · nonDerivative · entry 2 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,496 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 27, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 27, 2020 Filed Dec 30, 2020 16:51 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 2,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012283 · edgar.xml · nonDerivative · entry 1 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,145 F1 · shares: This reflects the number of restricted stock units that became vested as of December 27, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 27, 2020. F3 · balance_after: Includes 1324 shares acquired under the Axogen, Inc. employee stock purchase plan on June 30, 2020. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 21:16 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-003916 · edgar.xml · derivative · entry 3 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 21:16 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-003916 · edgar.xml · derivative · entry 2 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 21:16 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 24,000 | $0.00 Strike: $8.61 | $0.00 |
DisclosureSEC source: 0001179110-20-003916 · edgar.xml · derivative · entry 1 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-03-16 F1 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2024 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:18 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 440 | $14.68 | $6,459.20 |
DisclosureSEC source: 0001179110-20-001942 · edgar.xml · nonDerivative · entry 2 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,521 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 18, 2020. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:18 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 1,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001942 · edgar.xml · nonDerivative · entry 1 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,961 F1 · shares: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. F1 · price: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 20:23 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 5 | $15.08 | $75.40 |
DisclosureSEC source: 0001179110-19-009512 · edgar.xml · nonDerivative · entry 13 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,635 Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 20:23 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 100 | $15.08 | $1,507.90 |
DisclosureSEC source: 0001179110-19-009512 · edgar.xml · nonDerivative · entry 12 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,630 Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 20:23 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 100 | $15.08 | $1,507.90 |
DisclosureSEC source: 0001179110-19-009512 · edgar.xml · nonDerivative · entry 11 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,530 Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 20:23 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 100 | $15.08 | $1,507.90 |
DisclosureSEC source: 0001179110-19-009512 · edgar.xml · nonDerivative · entry 10 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,430 Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 20:23 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 100 | $15.12 | $1,512.00 |
DisclosureSEC source: 0001179110-19-009512 · edgar.xml · nonDerivative · entry 9 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,330 Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 20:23 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 200 | $15.11 | $3,022.00 |
DisclosureSEC source: 0001179110-19-009512 · edgar.xml · nonDerivative · entry 8 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,230 Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 20:23 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 100 | $15.12 | $1,512.00 |
DisclosureSEC source: 0001179110-19-009512 · edgar.xml · nonDerivative · entry 7 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,030 Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 20:23 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 100 | $15.11 | $1,511.00 |
DisclosureSEC source: 0001179110-19-009512 · edgar.xml · nonDerivative · entry 6 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,930 Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 20:23 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 100 | $15.12 | $1,512.00 |
DisclosureSEC source: 0001179110-19-009512 · edgar.xml · nonDerivative · entry 5 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,830 Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 20:23 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 8 | $15.12 | $120.96 |
DisclosureSEC source: 0001179110-19-009512 · edgar.xml · nonDerivative · entry 4 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,730 Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 20:23 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 4 | $15.12 | $60.48 |
DisclosureSEC source: 0001179110-19-009512 · edgar.xml · nonDerivative · entry 3 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,722 Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 20:23 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 88 | $15.12 | $1,330.56 |
DisclosureSEC source: 0001179110-19-009512 · edgar.xml · nonDerivative · entry 2 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,718 Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 20:23 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 4,630 | $15.11 | $69,959.30 |
DisclosureSEC source: 0001179110-19-009512 · edgar.xml · nonDerivative · entry 1 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,630 Read SEC document |
| December 27, 2018 Filed Dec 31, 2018 21:35 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 4,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-014317 · edgar.xml · derivative · entry 2 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,600 Underlying: Common Stock · 4,600 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 27, 2018 Filed Dec 31, 2018 21:35 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 23,200 | $0.00 Strike: $19.17 | $0.00 |
DisclosureSEC source: 0001179110-18-014317 · edgar.xml · derivative · entry 1 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,200 Underlying: Common Stock · 23,200 shares Expires 2028-12-27 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 27, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 12:47 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 40,000 | $0.00 Strike: $38.25 | $0.00 |
DisclosureSEC source: 0001179110-18-012518 · edgar.xml · derivative · entry 1 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-11-01 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on November 1, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on November 1, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.